November 7, 2016 / 12:28 PM / 9 months ago

BRIEF-Kedrion Biopharma and Kamada announce FDA acceptance of BLA submission

Nov 7 (Reuters) - Kamada Ltd

* Says FDA has assigned a prescription drug user fee act (PDUFA) goal date of August 29, 2017, for completion of review of BLA

* Kedrion Biopharma and Kamada announce FDA acceptance of BLA submission for human rabies immunoglobulin as a post-exposure treatment Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below